Antengene Corporation Limited

Antengene Corporation Limited (SEHK: 6996.HK) is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs. Its pipeline spans preclinical to commercial stages, with key investigational candidates including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 x 4-1BB bispecific antibody), ATG-125 (B7-H3 × PD-L1 bispecific ADC), ATG-207 (αCD3-TGF-β bifunctional fusion protein), and T cell engager (TCE) programs developed using its proprietary AnTenGager® platform. The company describes its work as harnessing science to improve the quality of life of cancer patients worldwide.

Antengene Corporation Limited (SEHK: 6996.HK) is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs. Its pipeline spans from preclinical to commercial stages, with key investigational candidates including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 x 4-1BB bispecific antibody), ATG-125 (B7-H3 × PD-L1 bispecific ADC), ATG-207 (αCD3-TGF-β bifunctional fusion protein), as well as T cell engager (TCE) programs developed using Antengene's proprietary AnTenGager® platform. AnTenGager® is described as Antengene's proprietary TCE 2.0 platform, featuring "2+1" bivalent binding for low expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform's broad applicability across autoimmune disease, solid tumors and hematological malignancies, with programs targeting CD19 x CD3 (ATG-201 for B cell-related autoimmune diseases; partnered with UCB), CDH6 x CD3 (ATG-106 for ovarian cancer and kidney cancer; partnered with K2 Therapeutics established by MPM BioImpact), ALPPL2 x CD3 (ATG-112 for gynecological tumors, digestive system malignancies, bladder cancer and NSCLC), LY6G6D x CD3 (ATG-110 for microsatellite-stable colorectal cancer), GPRC5D x CD3 (ATG-021 for multiple myeloma), and LILRB4 x CD3 (ATG-102 for acute myeloid leukemia and chronic myel...). The company's stated aim is harnessing science to improve the quality of life of cancer patients worldwide.

• Antengene announces first patient dosed in pivotal Phase III CLINCH-3 study of ATG-022 (CLDN18.2 ADC).

• Antengene publishes preclinical research paper on CD73 small molecule inhibitor ATG-037 combined with selinexor in Cancer Gene Therapy.

• Antengene to attend BioCon China Expo 2026 as a round-table panelist.

A global, R&D-driven, commercial-stage biotech company focused on first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs.

• ATG-022

  CLDN18.2 ADC; Phase II program efficacious in Claudin 18.2 ultra-low expressors; being studied in 3L+ CLDN18.2+ Gastric / GEJ Cancer, 1L CLDN18.2+ Gastric/GEJ Cancer, 2L CLDN18.2+ Gastric/GEJ Cancer, CLDN18.2+ Undisclosed Non-GI Tumor, and other CLDN18.2+ Solid Tumors, including monotherapy (CLINCH) and combination with pembrolizumab and CAPOX (CLINCH-2) and combination with pembrolizumab (CLINCH-2).

• ATG-037

  Oral CD73 small molecule inhibitor with robust PoC data in reversing anti-PD-1 resistance; studied in CPI-resistant Melanoma.

• ATG-101

  PD-L1 x 4-1BB bispecific antibody overcoming liver toxicity.

• ATG-125

  B7-H3 × PD-L1 bispecific ADC.

• ATG-207

  αCD3-TGF-β bifunctional fusion protein.

• ATG-201

  CD19 x CD3 TCE for B cell-related autoimmune diseases; partnered with UCB; Phase I ATTRACT study received clinical trial approval in Australia.

• ATG-106

  CDH6 x CD3 TCE for ovarian cancer and kidney cancer; partnered with K2 Therapeutics established by MPM BioImpact.

• ATG-112

  ALPPL2 x CD3 TCE for gynecological tumors, digestive system malignancies, bladder cancer and NSCLC.

• ATG-110

  LY6G6D x CD3 TCE for microsatellite-stable colorectal cancer.

• ATG-021

  GPRC5D x CD3 TCE for multiple myeloma.

• ATG-102

  LILRB4 x CD3 TCE for acute myeloid leukemia and chronic myel...

1. 1德琪医药antengene.com
2. 2About Antengeneantengene.com
3. 3Our Productsantengene.com
4. 4Antengene Corporation Limited (China)wikidata.org